Literature DB >> 18516528

Skip metastases in medullary thyroid carcinoma: a single-center experience.

Marcos R Tavares1, Pedro Michaluart, Fabio Montenegro, Sergio Arap, Maria Sodre, Flavio Takeda, Lenine Brandao, Sergio Toledo, Alberto Ferraz.   

Abstract

PURPOSE: Total thyroidectomy (TT) with level VI and VII central neck dissection is the initial treatment for medullary thyroid carcinoma (MTC) without identifiable neck metastasis. Level II to V lateral neck dissection is performed if neck metastasis is present or suspected. We conducted this study to identify the frequency and clinical determinants of skip neck metastasis in MTC.
METHODS: We reviewed the medical records of 32 patients who underwent TT and bilateral neck dissection for MTC. The clinical features were correlated with pN status in the central versus lateral compartments of the neck.
RESULTS: Neck lymph node metastasis (pN+) was found in 20 patients (62.5%) and skip metastases were found in 7 (35%) patients. The sensitivity of the pN status of the central compartment of the neck to predict the pN status of the lateral compartment of the neck was 53.8% and specificity was 63.2%. We found pN+ in 90% of the patients with lymph nodes >15 mm in diameter versus 50% in those with lymph nodes <15 mm in diameter.
CONCLUSIONS: There is skip metastasis in MTC. It is unsafe to use the lymph node status of the central compartment of the neck to define the pN status of the lateral neck. A lymph node greater than 15 mm in diameter is related to pN status.

Entities:  

Mesh:

Year:  2008        PMID: 18516528     DOI: 10.1007/s00595-007-3664-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  17 in total

1.  German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2.

Authors:  F Raue
Journal:  Langenbecks Arch Surg       Date:  1998-10       Impact factor: 3.445

2.  Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.

Authors:  Gabriela E Sanso; Horacio M Domene; RudazMariaC Garcia; Eduardo Pusiol; MondinoAnaK de; Maria Roque; Alejandro Ring; Hector Perinetti; Boris Elsner; Sonia Iorcansky; Marta Barontini
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

3.  Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma.

Authors:  O Gimm; J Ukkat; H Dralle
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

4.  Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.

Authors:  T Weber; T Schilling; K Frank-Raue; M Colombo-Benkmann; U Hinz; R Ziegler; E Klar
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

Review 5.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

6.  Repeat mediastinal lymph-node dissection for palliation in advanced medullary thyroid carcinoma.

Authors:  A Machens; O Gimm; J Ukkat; T Sutter; H Dralle
Journal:  Langenbecks Arch Surg       Date:  1999-06       Impact factor: 3.445

7.  Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.

Authors:  E Kebebew; P H Ituarte; A E Siperstein; Q Y Duh; O H Clark
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

8.  The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study.

Authors:  H Dralle; G F Scheumann; C Proye; F Bacourt; A Frilling; F Limbert; G Gheri; J F Henry; M Berner; B Niederle
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

9.  Surgical management of patients with persistent or recurrent medullary thyroid cancer.

Authors:  J F Moley; M K Debenedetti; W G Dilley; L E Tisell; S A Wells
Journal:  J Intern Med       Date:  1998-06       Impact factor: 8.989

10.  Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.

Authors:  S A Wells; D D Chi; K Toshima; L P Dehner; C M Coffin; S B Dowton; J L Ivanovich; M K DeBenedetti; W G Dilley; J F Moley
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

View more
  10 in total

1.  Endoscopic thyroidectomy and sentinel lymph node biopsy via an anterior chest approach for papillary thyroid cancer.

Authors:  Ja Seong Bae; Woo Chan Park; Byung Joo Song; Sang Seol Jung; Jeong Soo Kim
Journal:  Surg Today       Date:  2009-02-07       Impact factor: 2.549

2.  Lentivirus-mediated silencing of MPHOSPH8 inhibits MTC proliferation and enhances apoptosis.

Authors:  Peiyong Li; Weiping Yang; Baiyong Shen; Hongwei Li; Jiqi Yan
Journal:  Oncol Lett       Date:  2016-05-06       Impact factor: 2.967

3.  The advantages of carbon nanoparticles in level VII lymph node dissection in patients with papillary thyroid cancer.

Authors:  Yijun Chen; Guolie Zhang; Yuanmei Lin; Guoliang Zhang; Jian Gao
Journal:  Gland Surg       Date:  2021-06

4.  Skip lateral lymph node metastasis leaping over the central neck compartment in papillary thyroid carcinoma.

Authors:  Jianyong Lei; Jinjing Zhong; Ke Jiang; Zhihui Li; Rixiang Gong; Jingqiang Zhu
Journal:  Oncotarget       Date:  2017-04-18

Review 5.  Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Marcelo Augusto Santos; Marcos R Tavares; Rodrigo A Toledo; Joya Emilie de Menezes Correia-Deur
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

6.  Extent of surgery in clinically evident but operable MTC - when is central and/or lateral lympadenectomy indicated?

Authors:  Oliver Gimm
Journal:  Thyroid Res       Date:  2013-03-14

Review 7.  Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2.

Authors:  Marcos R Tavares; Sérgio P A Toledo; Fábio L M Montenegro; Raquel A Moyses; Rodrigo A Toledo; Tomoko Sekyia; Claudio R Cernea; Lenine G Brandão
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

8.  Sporadic medullary thyroid carcinoma: clinical data from a university hospital.

Authors:  Joya Emilie M Correia-Deur; Rodrigo A Toledo; Alice T Imazawa; Delmar M Lourenço; Marilza C L Ezabella; Marcos R Tavares; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

9.  Reduced USP39 expression inhibits malignant proliferation of medullary thyroid carcinoma in vitro.

Authors:  Yong An; Shuwen Yang; Kai Guo; Ben Ma; Yu Wang
Journal:  World J Surg Oncol       Date:  2015-08-25       Impact factor: 2.754

10.  Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice.

Authors:  Xianying Meng; Qiang Zhang; Guibin Zheng; Renzhu Pang; Tebo Hua; Shuai Yang; Jie Li
Journal:  Oncol Lett       Date:  2014-04-09       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.